Vertex Information Rights. 10.7.1. If Vertex determines in good faith that Company is an entity that is subject to financial consolidation with Vertex for the purposes of its quarterly and annual financial statements (or otherwise requires such information in order to comply with GAAP), Company will make available to Vertex:
Appears in 3 contracts
Samples: Strategic Collaboration and License Agreement (Verve Therapeutics, Inc.), Collaboration and License Agreement (Affinia Therapeutics Inc.), Collaboration and License Agreement (Affinia Therapeutics Inc.)
Vertex Information Rights. 10.7.1. If Vertex determines in good faith that Company is an entity that is subject to financial consolidation with Vertex for the purposes of its quarterly and annual financial statements (or otherwise requires such information in order to comply with GAAP), Company will make available to Vertex:
Appears in 3 contracts
Samples: Strategic Collaboration and License Agreement (Entrada Therapeutics, Inc.), Strategic Collaboration and License Agreement (Entrada Therapeutics, Inc.), Strategic Collaboration and License Agreement (Entrada Therapeutics, Inc.)
Vertex Information Rights. 10.7.1. If Vertex determines in good faith upon advice of its independent financial auditor that Company is an entity that is subject to financial consolidation with Vertex for the purposes of its quarterly and annual financial statements (or otherwise requires such information in order to comply with GAAP), Company will make available to Vertex:
Appears in 1 contract
Samples: Master Collaboration Agreement (Molecular Templates, Inc.)
Vertex Information Rights. 10.7.1. 12.7.1 If Vertex determines in good faith upon advice of its independent financial auditor that Company is an entity that is subject to financial consolidation with Vertex for the purposes of its quarterly and annual financial statements (or otherwise requires such information in order to comply with GAAP), Company will make available to Vertex:
Appears in 1 contract
Samples: Master Collaboration Agreement (Kymera Therapeutics, Inc.)